v3.25.2
Insider Trading Arrangements
3 Months Ended
Jun. 30, 2025
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Kevin McLaughlin [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On May 12, 2025, Kevin McLaughlin, a member of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 35,000 shares of our common stock between November 10, 2025 and November 30, 2026;
Name Kevin McLaughlin
Title member of the Vericel Corporation Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 12, 2025
Expiration Date November 30, 2026
Arrangement Duration 385 days
Aggregate Available 35,000
Robert Zerbe [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On May 23, 2025, Robert Zerbe, Chairman of the Vericel Corporation Board of Directors, entered into a Rule 10b5-1 trading arrangement providing for the potential sale of up to 7,500 shares of our common stock between September 2, 2025 and August 28, 2026; and
Name Robert Zerbe
Title Chairman of the Vericel Corporation Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 23, 2025
Expiration Date August 28, 2026
Arrangement Duration 360 days
Aggregate Available 7,500
Jonathan Hopper [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On May 30, 2025, Jonathan Hopper, Vericel Corporation’s Chief Medical Officer, entered into a 10b5-1 Plan providing for the potential sale of up to 37,847 shares of our common stock between September 2, 2025 and August 28, 2026.
Name Jonathan Hopper
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date May 30, 2025
Expiration Date August 28, 2026
Arrangement Duration 360 days
Aggregate Available 37,847